EXECUTIVE ENGAGEMENTS
OUTREACH
798
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
162
Interactions with Platform & by Email
PARTICIPANTS
32
Unique # Participated
VALIDATIONS
14
Responses Validated*
COMPETITORS
24
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
18
PAGES
72
EDITION
18
PRICE
USD $5600
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Sepsis Therapeutics estimated at US$14.8 Million in the year 2020, is projected to reach a revised size of US$765 Million by 2027, growing at a CAGR of 75.7% over the period 2020-2027.
The Sepsis Therapeutics market in the U.S. is estimated at US$4.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$116.6 Million by the year 2027 trailing a CAGR of 71.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 67.9% and 64.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 51.3% CAGR.
SELECT PLAYERS
Adrenomed AG; AM-Pharma B.V.; Aridis Pharmaceuticals Inc.; Asahi Kasei Pharma America; Astellas Pharma Inc.; Endacea Inc.; InflaRx GmbH; La Jolla Pharmaceutical Company; Opsonix, Inc.; T2 Biosystems Inc.; TaiRx Inc.
SEGMENTS
» Segment (Sepsis Therapeutics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Sepsis - A Prelude |
| Recent Market Activity |
| New Treatment Protocols and New Definitions - Every Minute Counts!! |
| Aging Population: A Key Growth Driver for Sepsis Therapeutics |
| Antibiotics and Vasopressors - The Current Standard of Care |
| Current Categories of Antibacterial Agents for First-line Sepsis Treatment |
| Current Anti-bacterial Drugs used in Sepsis |
| Current Antifungals used for Sepsis |
| Current Antivirals used for Sepsis |
| GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment |
| Argipressin Gains Approval for Septic Shock in 26 EU countries |
| Current & Future Analysis |
| Growth Drivers in a Nutshell |
| Market Restraints |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Adrenomed AG (Germany) |
| AM-Pharma B.V. (Netherlands) |
| AMOMED Pharma GmbH (Austria) |
| Asahi Kasei Pharma America (USA) |
| Endacea, Inc. (USA) |
| InflaRx N.V. (Germany) |
| La Jolla Pharmaceutical Company (USA) |
| TaiRx, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| A Market Characterized by High Unmet Medical Needs |
| Research Activity Enables Increased Awareness of Disease Pathogenesis |
| Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018 |
| Select Sepsis Therapeutics under Phase III Clinical Trials: 2018 |
| Novel Immune-Specific Modes of Action under Focus |
| Emphasizing on Endothelial Cell Function |
| HMGB1 - A Potential Target for Future Therapies |
| Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management |
| Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients |
| Hydrocortisone Displays Potential in Septic Shock Treatment |
| Reduced Levels of Vitamin C Characterize Sepsis Patients |
| Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate |
| Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market |
| Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models |
| World Sepsis Day Aims to Result in Improvement in Sepsis Management |
| NSAIDs Demonstrate Potential to Treat Sepsis |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| CANADA |
| Canada Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| JAPAN |
| Japan Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| CHINA |
| China Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| EUROPE |
| Europe Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| GERMANY |
| Germany Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| ITALY |
| Italy Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UNITED KINGDOM |
| UK Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| IV. COMPETITION |
| Total Companies Profiled: 24 |
The World of Sepsis Therapeutics is Changing Fast!
It's Time to Identify Upcoming Revenue Pockets & Growth Areas.
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com